FDA Accepts for Review Resubmitted NDA for TransCon PTH (palopegteriparatide) in Adult Patients with Hypoparathyroidism

COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) --Ascendis Pharma, Inc. (Nasdaq: ASND) today announced that the U.S. Food& Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news